Brand Name

Zunveyl

Generic Name
Benzgalantamine
View Brand Information
FDA approval date: August 09, 2024
Form: Tablet

What is Zunveyl (Benzgalantamine)?

ZUNVEYL is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults

Approved To Treat

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment